How CAR T-Cell Therapy Is Moving Beyond Blood Cancers Into Solid Tumors
Chimeric antigen receptor (CAR) T-cell therapy is moving beyond blood cancers through biomarker-selected trials, smarter cell engineering, and delivery methods built for solid tumor biology. It is not yet a standard United States treatment for any…

